Mirena™ is a levonorgestrel-releasing intrauterine system providing long-term contraception. As of February 2014, approximately 1,450 women have filed claims against Bayer in the U.S. Most of the cases pending in U.S. federal courts have been consolidated in a multidistrict litigation (MDL) in the Southern District of New York. Additional lawsuits are anticipated. Plaintiffs claim personal injuries resulting from the use of Mirena™, including perforation of the uterus or ectopic pregnancy, and seek compensatory and punitive damages. Plaintiffs allege that Mirena™ is defective and that Bayer knew or should have known of the risks associated with it and failed to adequately warn its users.
 Bayer Annual Report 2013 (February 28, 2014).
NuvaRing(™) is a flexible ring that delivers low doses of estrogen and progestin. Although the primary effect is to inhibit ovulation, other alterations include changes in the cervical mucus (which increases difficulty of sperm entry) and changes to the lining of the uterus (to reduce the likelihood of implantation). NuvaRing(™) is designed to be inserted into the vagina once every three weeks to prevent pregnancy.
Since its entry into the market in 2002, FDA has received an increasing number of reports of women using NuvaRing(™) suffering from blood clots and other injuries. The greatest health risks for NuvaRing(™) are for women who are heavy smokers (15 or more a day) and are over 35 years old. In 2011, FDA warned that the hormones released by vaginal ring contraceptives may increase the risk of blood clots, deep vein thrombosis (DVT), and other harmful side effects such as gallbladder disease.
The company that sells NuvaRing(™), Merck & Co., is now defending against over 1,500 lawsuits consolidated in a special federal multi-litigation (MDL) court in the Eastern District of Missouri. Plaintiffs claim that Merck failed to adequately warn of the risks associated with the use of the product, and/or that the NuvaRing product is otherwise defective and unreasonably dangerous. The MDL is currently is discovery proceedings.
 NIH, Daily Med Current Medication Information, NUVARING (etonogestrel and ethinyl estradiol) insert, extended release [Physicians Total Care, Inc.] (2/2012)
 United States District Court, E.D. Missouri, In Re: NuvaRing, 4:-08-md-01964-RWS.
Contraceptive Device Alerts
If you have experienced adverse events or side effects from a contraceptive device find help here.
Statutes of Limitations limit the time period that plaintiffs have to file a legal claim. These time limits vary from state to state, but generally range from 2-6 years. In product liability cases, the statute of limitations usually begins when the injury occurs, but in some cases may not start until the affected person discovers, or should have discovered, that the product caused their injury. More info
Looking for Information About Oral Contraception?